Experimental Artery-Directed chemo for rare brain tumors: tiny trial ends early

NCT ID NCT04994977

Terminated Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested giving chemotherapy drugs directly into the brain's arteries to treat two rare types of choroid plexus tumors. The goal was to shrink the tumor before a second surgery. Only 1 person was enrolled, and the study was terminated, so we have very little information about safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Melphalan, carboplatin, and topotecan (chemotherapy drugs given directly into an artery)
What this could lead to: If it works, this approach could shrink these rare brain tumors before surgery, making the operation safer and more effective.
What could go wrong: This was a very early Phase 1 trial with only 1 participant, so we don't know if it's safe or effective. The study was terminated, meaning results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL CHOROID PLEXUS PAPILLOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical choroid plexus papilloma choroid plexus carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATYPICAL CHOROID PLEXUS PAPILLOMA CHOROID PLEXUS CARCINOMA

Contacts and locations

Locations

Weill Cornell Medicine

New York, New York, 10025, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.